CN105997902A - Ambroxol hydrochloride composition serving as medicine for treating respiratory system diseases - Google Patents
Ambroxol hydrochloride composition serving as medicine for treating respiratory system diseases Download PDFInfo
- Publication number
- CN105997902A CN105997902A CN201610598760.6A CN201610598760A CN105997902A CN 105997902 A CN105997902 A CN 105997902A CN 201610598760 A CN201610598760 A CN 201610598760A CN 105997902 A CN105997902 A CN 105997902A
- Authority
- CN
- China
- Prior art keywords
- ambroxol hydrochloride
- medicine
- freeze
- ambroxol
- respiratory system
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- QNVKOSLOVOTXKF-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 QNVKOSLOVOTXKF-UHFFFAOYSA-N 0.000 title claims abstract description 65
- 229960000985 ambroxol hydrochloride Drugs 0.000 title claims abstract description 65
- 239000003814 drug Substances 0.000 title claims abstract description 41
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 208000023504 respiratory system disease Diseases 0.000 title claims abstract description 11
- 239000000843 powder Substances 0.000 claims abstract description 21
- 239000013078 crystal Substances 0.000 claims abstract description 19
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 9
- 229930195725 Mannitol Natural products 0.000 claims abstract description 9
- 239000000594 mannitol Substances 0.000 claims abstract description 9
- 235000010355 mannitol Nutrition 0.000 claims abstract description 9
- 238000010438 heat treatment Methods 0.000 claims description 21
- 238000004108 freeze drying Methods 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 238000001291 vacuum drying Methods 0.000 claims description 16
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 14
- -1 ambroxol compound Chemical class 0.000 claims description 14
- 238000009413 insulation Methods 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 14
- 229960005174 ambroxol Drugs 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- 238000004821 distillation Methods 0.000 claims description 7
- 238000007710 freezing Methods 0.000 claims description 7
- 230000008014 freezing Effects 0.000 claims description 7
- 239000012528 membrane Substances 0.000 claims description 7
- 230000000630 rising effect Effects 0.000 claims description 7
- 230000001954 sterilising effect Effects 0.000 claims description 7
- 239000008215 water for injection Substances 0.000 claims description 7
- 229910017488 Cu K Inorganic materials 0.000 claims description 4
- 229910017541 Cu-K Inorganic materials 0.000 claims description 4
- 230000005260 alpha ray Effects 0.000 claims description 4
- 238000005259 measurement Methods 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 abstract description 25
- 238000012360 testing method Methods 0.000 abstract description 11
- 238000002347 injection Methods 0.000 abstract description 9
- 239000007924 injection Substances 0.000 abstract description 9
- 238000000634 powder X-ray diffraction Methods 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000012046 mixed solvent Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 6
- 241001289435 Astragalus brachycalyx Species 0.000 description 5
- 235000002917 Fraxinus ornus Nutrition 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 206010036790 Productive cough Diseases 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 238000004088 simulation Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- XBFISNPWDYRTRZ-UHFFFAOYSA-N N.Cl.[Br] Chemical class N.Cl.[Br] XBFISNPWDYRTRZ-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000003580 lung surfactant Substances 0.000 description 1
- 230000000510 mucolytic effect Effects 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/10—Separation; Purification; Stabilisation; Use of additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/44—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton bound to carbon atoms of the same ring or condensed ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention discloses an ambroxol hydrochloride composition serving as a medicine for treating respiratory system diseases and belongs to the technical field of medicines. A freeze-dried powder injection composition is prepared from ambroxol hydrochloride and mannitol; the ambroxol hydrochloride is a novel crystal compound; an X-ray powder diffraction pattern obtained by using Cu-Kalpha rays to measure is as shown in a figure 1; the ambroxol hydrochloride is ambroxol hydrochloride different from that reported in the prior art. The ambroxol hydrochloride composition is found by tests to have better solubleness and higher stability and is convenient for preparation of various preparations; the freeze-dried powder injection composition prepared from the ambroxol hydrochloride composition provided by the invention is simple in composition and good in stability.
Description
The application is that the application for a patent for invention that applicant Miao Yiwen proposes is (invention entitled: one treats respiratory system disease
Sick medicine ambroxol hydrochloride composition, Application No.: 2015102479443, filing date: on May 15th, 2015) division
Application.
Technical field
The invention belongs to pharmaceutical technology field, relate to a kind of medicine ambroxol hydrochloride treating respiratory system disease
Thing.
Background technology
Ambroxol hydrochloride (Ambroxol Hydrochloride) has another name called Ambroxol Hydrochloride, be a kind of respiratory tract lubrication expectorant and
Mucolytic, ambroxol hydrochloride, chemical name is trans-4-[(2-amino-3,5-dibromo-benzyl) amino] Hexalin hydrochloric acid
Salt, for white to slightly yellow crystalline powder；Ambroxol hydrochloride has mucus and gets rid of facilitation and dissolve the characteristic of secretions,
It can promote the eliminating of thick secretions in respiratory tract and reduce the delay of mucus, thus remarkably promotes expectoration, improves and breathes shape
Condition.The secretion of pulmonary surfactant, the secretion of air flue liquid and ciliary movement can be promoted.Ambroxol hydrochloride is the most extensively used
The thick sputum that causes in various acute and chronic respiratory tract diseases, dys-expectoration etc..
Polymorphic currently, with respect to ambroxol hydrochloride has been disclosed for a lot of patent and document.
Patent ZL201210513123.6 discloses a kind of ambroxol hydrochloride crystal formation and the medicine prepared by this crystal formation
Compositions, described ambroxol hydrochloride crystal formation in the X-ray powder diffraction pattern represented with the 2 θ ± 0.2 ° angles of diffraction at 6.9 °,
7.2 °, 12.8 °, 15.6 °, 17.5 °, 20 °, 21 °, 22 °, at 24 °, demonstrate characteristic diffraction peak.
Patent ZL201210231927.7 relates to a kind of unformed ambroxol compound and preparation method thereof, and this nothing is fixed
The X-ray powder diffraction pattern of type powder is without obvious characteristic peak.
Patent application 201410071920.2 relates to a kind of ambroxol compound and oral cavity disintegration tablet.The salt of the present invention
The X-ray powder diagram that acid ambroxol use Cu-K alpha ray measurement obtains is as shown in Figure 1.Orally disintegrating tablet of ambroxol hydrochloride
In containing ambroxol hydrochloride 10～30 weight portion, filler 50～80 weight portion, disintegrating agent 10～15 weight portion, fluidizer 0.3
～1.6 weight portions, lubricant 0.4～1.6 weight portion, correctives 8～16 weight portion.
Ambroxol hydrochloride is insoluble in water, and the preparation to preparation brings the biggest difficulty, and the present invention proposes a kind of new hydrochloric acid
Ammonia bromine compounds, has preferable dissolubility and higher stability, facilitates the preparation of various preparation, utilize the present invention to provide
The lyophilized injectable powder component that ambroxol hydrochloride crystal-form compound is made is simple, good stability.
Summary of the invention
The goal of the invention of the present invention is to provide a kind of medicine ambroxol hydrochloride composition treating respiratory system disease.
In order to complete the purpose of the present invention, the technical scheme of employing is:
The present invention relates to a kind of medicine ambroxol hydrochloride composition treating respiratory system disease, wherein said compositions is by salt
Acid ambroxol, mannitol composition；Described ambroxol hydrochloride is crystal, uses the X-ray powder that Cu-K alpha ray measurement obtains
Diffraction pattern is as shown in Figure 1.
Preferably, above-mentioned ambroxol hydrochloride is 1:3.5-10 with the weight ratio of mannitol.
Preferably, above-mentioned ambroxol hydrochloride is 1:5.5-8 with the weight ratio of mannitol.
Preferably, above-mentioned ambroxol hydrochloride is 1:6 with the weight ratio of mannitol.
The preparation method of described compositions comprises the following steps:
Take above-mentioned ambroxol compound, use water for injection stirring and dissolving, add the mannitol of recipe quantity, regulate pH value, so
After 20 minutes pH of rear stirring are constant, mend and inject water to 10L, then use activated carbon coarse filtration, successively through 1.0 μm, 0.45 μm,
The microporous filter membrane aseptic filtration of 0.22 μm, filters into sterilizing room, measure pH and content qualified after, fill, pressure half plug, put into and lower the temperature
To the freeze drying box of-50 DEG C, 35 hours tamponade outlets of frozen drying, roll lid.
Preferably, the above regulation pH is 5.5-6.5.
Preferably, the above frozen drying process is:
Pre-freeze: medicine being put into freeze drying box freezing, temperature is-50 DEG C, and the time is 100min；
Distillation: after medicine freezes, starts vacuum machine and is evacuated to 10Pa, close fridge, and heating up to medicine makes to freeze product temperature
Rising to-20 DEG C, the time is 20 hours 20min；
It is dried: medicine is gradually heating to 0 DEG C, insulation vacuum drying 10h, is continuously heating to 25 DEG C of insulation vacuum drying 3h.
The preparation method of the ambroxol hydrochloride crystal in the present composition comprises the following steps:
(1) ambroxol hydrochloride solid is added in the mixed solvent of methanol, 2-methyltetrahydrofuran and acetonitrile, the body of mixed solvent
Amassing 8 times for ambroxol hydrochloride weight, the volume ratio of methanol, 2-methyltetrahydrofuran and acetonitrile is 8:3.5:2.5；
(2) control temperature under conditions of 35-45 DEG C, the solution that step (1) obtains adds the mixed of ethanol and ethyl acetate
Bonding solvent, the volume of mixed solvent is 10 times of ambroxol hydrochloride weight, and the volume ratio of ethanol and ethyl acetate is 5:1.5；
(3), after adding the mixed solvent of ethanol and ethyl acetate, it is cooled to-10 DEG C with speed for 3-4.5 DEG C/min, at-10 DEG C
Stand 5-7 hour, separate out crystal, filter, filter cake washing with alcohol, after vacuum drying, obtain ambroxol compound.
Below technical scheme is made further explanation:
The present invention, by the precise controlling to crystallization condition, has prepared a kind of ambroxol hydrochloride unlike the prior art the most brilliant
Type, the X-ray powder diagram of this ambroxol hydrochloride crystal is unlike the prior art.Simultaneously because the ins and outs of this crystal formation,
Find that through test the new hydrochloric acid ammonia bromine compounds that the present invention proposes has preferable dissolubility and higher stability, convenient
The preparation of various preparations, the lyophilized injectable powder component utilizing the present invention to provide the ambroxol hydrochloride crystal-form compound to make is simple,
Good stability.
Accompanying drawing explanation
Fig. 1 is the X-ray powder diffraction spectrum of the ambroxol hydrochloride crystal of the embodiment of the present invention 1 preparation.
Detailed description of the invention
Below by specific embodiment, the summary of the invention of the present invention is described in further detail, but the most therefore limits
Determine present disclosure.
Embodiment 1: the preparation of ambroxol hydrochloride crystal
(1) ambroxol hydrochloride solid is added in the mixed solvent of methanol, 2-methyltetrahydrofuran and acetonitrile, the body of mixed solvent
Amassing 8 times for ambroxol hydrochloride weight, the volume ratio of methanol, 2-methyltetrahydrofuran and acetonitrile is 8:3.5:2.5；
(2) control temperature under conditions of 35-45 DEG C, the solution that step (1) obtains adds the mixed of ethanol and ethyl acetate
Bonding solvent, the volume of mixed solvent is 10 times of ambroxol hydrochloride weight, and the volume ratio of ethanol and ethyl acetate is 5:1.5；
(3), after adding the mixed solvent of ethanol and ethyl acetate, it is cooled to-10 DEG C with speed for 3-4.5 DEG C/min, at-10 DEG C
Stand 5-7 hour, separate out crystal, filter, filter cake washing with alcohol, after vacuum drying, obtain ambroxol compound.
The ambroxol hydrochloride crystal prepared uses X-ray powder diagram such as Fig. 1 that Cu-K alpha ray measurement obtains
Shown in, its purity of high-performance liquid chromatogram determination is 99.99%.
Embodiment 2: the preparation of ambroxol hydrochloride freeze-dried powder injection agent, step is as follows:
Take the ambroxol hydrochloride crystal 30g of the embodiment of the present invention 1 preparation, use water for injection stirring and dissolving, add the manna of 105g
Alcohol, regulation pH value is 5.5-6.5, after then 20 minutes pH of stirring are constant, mend and injects water to 10L, then thick with activated carbon
Filter, successively through 1.0 μm, 0.45 μm, the microporous filter membrane aseptic filtration of 0.22 μm, filter into sterilizing room, measure pH and content qualified after,
Fill, pressure half plug, put into and be cooled in the freeze drying box of-50 DEG C, 35 hours tamponade outlets of frozen drying, roll lid.
Lyophilization is divided into pre-freeze, distils and be dried:
Pre-freeze: medicine being put into freeze drying box freezing, temperature is-50 DEG C, and the time is 100min;
Distillation: after medicine freezes, starts vacuum machine and is evacuated to 10Pa, close fridge, and heating up to medicine makes to freeze product temperature
Rising to-20 DEG C, the time is 20 hours 20min；
It is dried: medicine is gradually heating to 0 DEG C, insulation vacuum drying 10h, is continuously heating to 25 DEG C of insulation vacuum drying 3h.
Embodiment 3: the preparation of ambroxol hydrochloride freeze-dried powder injection agent, step is as follows:
Take the ambroxol hydrochloride crystal 30g of the embodiment of the present invention 1 preparation, use water for injection stirring and dissolving, add the manna of 165g
Alcohol, regulation pH value is 5.5-6.5, after then 20 minutes pH of stirring are constant, mend and injects water to 10L, then thick with activated carbon
Filter, successively through 1.0 μm, 0.45 μm, the microporous filter membrane aseptic filtration of 0.22 μm, filter into sterilizing room, measure pH and content qualified after,
Fill, pressure half plug, put into and be cooled in the freeze drying box of-50 DEG C, 35 hours tamponade outlets of frozen drying, roll lid.
Lyophilization is divided into pre-freeze, distils and be dried:
Pre-freeze: medicine being put into freeze drying box freezing, temperature is-50 DEG C, and the time is 100min;
Distillation: after medicine freezes, starts vacuum machine and is evacuated to 10Pa, close fridge, and heating up to medicine makes to freeze product temperature
Rising to-20 DEG C, the time is 20 hours 20min；
It is dried: medicine is gradually heating to 0 DEG C, insulation vacuum drying 10h, is continuously heating to 25 DEG C of insulation vacuum drying 3h.
Embodiment 4: the preparation of ambroxol hydrochloride freeze-dried powder injection agent, step is as follows:
Take the ambroxol hydrochloride crystal 30g of the embodiment of the present invention 1 preparation, use water for injection stirring and dissolving, add the manna of 180g
Alcohol, regulation pH value is 5.5-6.5, after then 20 minutes pH of stirring are constant, mend and injects water to 10L, then thick with activated carbon
Filter, successively through 1.0 μm, 0.45 μm, the microporous filter membrane aseptic filtration of 0.22 μm, filter into sterilizing room, measure pH and content qualified after,
Fill, pressure half plug, put into and be cooled in the freeze drying box of-50 DEG C, 35 hours tamponade outlets of frozen drying, roll lid.
Lyophilization is divided into pre-freeze, distils and be dried:
Pre-freeze: medicine being put into freeze drying box freezing, temperature is-50 DEG C, and the time is 100min;
Distillation: after medicine freezes, starts vacuum machine and is evacuated to 10Pa, close fridge, and heating up to medicine makes to freeze product temperature
Rising to-20 DEG C, the time is 20 hours 20min；
It is dried: medicine is gradually heating to 0 DEG C, insulation vacuum drying 10h, is continuously heating to 25 DEG C of insulation vacuum drying 3h.
Embodiment 5: the preparation of ambroxol hydrochloride freeze-dried powder injection agent, step is as follows:
Take the ambroxol hydrochloride crystal 30g of the embodiment of the present invention 1 preparation, use water for injection stirring and dissolving, add the manna of 240g
Alcohol, regulation pH value is 5.5-6.5, after then 20 minutes pH of stirring are constant, mend and injects water to 10L, then thick with activated carbon
Filter, successively through 1.0 μm, 0.45 μm, the microporous filter membrane aseptic filtration of 0.22 μm, filter into sterilizing room, measure pH and content qualified after,
Fill, pressure half plug, put into and be cooled in the freeze drying box of-50 DEG C, 35 hours tamponade outlets of frozen drying, roll lid.
Lyophilization is divided into pre-freeze, distils and be dried:
Pre-freeze: medicine being put into freeze drying box freezing, temperature is-50 DEG C, and the time is 100min;
Distillation: after medicine freezes, starts vacuum machine and is evacuated to 10Pa, close fridge, and heating up to medicine makes to freeze product temperature
Rising to-20 DEG C, the time is 20 hours 20min；
It is dried: medicine is gradually heating to 0 DEG C, insulation vacuum drying 10h, is continuously heating to 25 DEG C of insulation vacuum drying 3h.
Embodiment 6: the preparation of ambroxol hydrochloride freeze-dried powder injection agent, step is as follows:
Take the ambroxol hydrochloride crystal 30g of the embodiment of the present invention 1 preparation, use water for injection stirring and dissolving, add the manna of 300g
Alcohol, regulation pH value is 5.5-6.5, after then 20 minutes pH of stirring are constant, mend and injects water to 10L, then thick with activated carbon
Filter, successively through 1.0 μm, 0.45 μm, the microporous filter membrane aseptic filtration of 0.22 μm, filter into sterilizing room, measure pH and content qualified after,
Fill, pressure half plug, put into and be cooled in the freeze drying box of-50 DEG C, 35 hours tamponade outlets of frozen drying, roll lid.
Lyophilization is divided into pre-freeze, distils and be dried:
Pre-freeze: medicine being put into freeze drying box freezing, temperature is-50 DEG C, and the time is 100min;
Distillation: after medicine freezes, starts vacuum machine and is evacuated to 10Pa, close fridge, and heating up to medicine makes to freeze product temperature
Rising to-20 DEG C, the time is 20 hours 20min；
It is dried: medicine is gradually heating to 0 DEG C, insulation vacuum drying 10h, is continuously heating to 25 DEG C of insulation vacuum drying 3h.
Experimental example 1: mobility is tested
The mobility of the ambroxol compound of the embodiment of the present invention 1 is detected by this experimental example, uses fixed funnel method,
The suitable height being placed on graph paper by funnel, makes ambroxol compound freely flow down from bell mouth, until the circle formed
Cone top contacts with bell mouth, measures hypotenuse and the horizontal angle (θ angle of repose) of ambroxol compound accumulation horizon.
Experimental result is as shown in table 1.
Table 1: mobility experimental result
From the interpretation of table 1, the mobility of the ambroxol compound that the embodiment of the present invention 1 prepares is fine.
Experimental example 2: dissolubility contrast test
The dissolubility of following ambroxol hydrochloride is detected,
Comparative example 1: commercially available ambroxol hydrochloride (Wuhan English and pharmaceutical Co. Ltd)；
Comparative example 2: prepare according to the embodiment 1 of patent ZL201210513123.6；
Comparative example 3: prepare according to the embodiment 1 of patent ZL201210231927.7；
Comparative example 4: prepare according to the embodiment 1 of patent application 201410071920.2；
1. measure the quality of ambroxol hydrochloride in 100g water saturation solution under the conditions of 20 DEG C；Experimental result is as shown in table 2.
Table 2 dissolubility comparative test result
As can be seen from Table 2, the water solublity of ambroxol hydrochloride of the present invention is greatly improved, and brings conveniently to preparation preparation.
Experimental example 3: influence factor tests
1. hot test
The lyophilized injectable powder that Example 4 prepares, simulation listing packaging, put in sealing clean container, in 40 ± 2 DEG C of temperature
Lower placement 10 days, in sampling in the 5th day and the 10th day, is detected by stability high spot reviews project, result of the test and 0 day ratio
Relatively.
2. high humility test
The lyophilized injectable powder that Example 4 prepares, simulation listing packaging, put in sealing clean container, at 25 ± 2 DEG C relatively
Place 10 days under conditions of humidity 90% ± 5%, in sampling in the 5th day and the 10th day, detect by stability high spot reviews project,
Result of the test compared with 0 day.
3. strong illumination test
The lyophilized injectable powder that Example 4 prepares, simulation listing packaging, put in sealing clean container, being placed in illumination is
Place 10 days under conditions of 4500lx, in sampling in the 5th day and the 10th day, detect by stability high spot reviews project, result
Compared with 0 day.Result see table:
Table 3 influence factor's result of the test
Result shows: ambroxol hydrochloride freeze-dried powder injection agent of the present invention, and its stability is good, at high temperature, high humidity, high light conditions
Under, all keep stable performance.The ambroxol hydrochloride freeze-dried powder injection agent that other embodiments of the invention are prepared carry out affecting because of
Element experiment, has obtained identical experimental result.
Claims (4)
1. the medicine ambroxol hydrochloride composition treating respiratory system disease, it is characterised in that: described compositions is by salt
Acid ambroxol, mannitol composition；Described ambroxol hydrochloride is crystal, uses the X-ray powder that Cu-K alpha ray measurement obtains
Diffraction pattern is as shown in Figure 1；In described compositions, ambroxol hydrochloride is 1:8 with the weight ratio of mannitol.
The medicine ambroxol hydrochloride composition for the treatment of respiratory system disease the most according to claim 1, it is characterised in that by
Following method prepares:
Take above-mentioned ambroxol compound, use water for injection stirring and dissolving, add the mannitol of recipe quantity, regulate pH value, so
After 20 minutes pH of rear stirring are constant, mend and inject water to 10L, then use activated carbon coarse filtration, successively through 1.0 μm, 0.45 μm,
The microporous filter membrane aseptic filtration of 0.22 μm, filters into sterilizing room, measure pH and content qualified after, fill, pressure half plug, put into and lower the temperature
To the freeze drying box of-50 DEG C, 35 hours tamponade outlets of frozen drying, roll lid.
The medicine ambroxol hydrochloride composition for the treatment of respiratory system disease the most according to claim 2, it is characterised in that: institute
Stating regulation pH is 5.5-6.5.
The medicine ambroxol hydrochloride composition for the treatment of respiratory system disease the most according to claim 2, it is characterised in that institute
Stating frozen drying process is:
Pre-freeze: medicine being put into freeze drying box freezing, temperature is-50 DEG C, and the time is 100min；
Distillation: after medicine freezes, starts vacuum machine and is evacuated to 10Pa, close fridge, and heating up to medicine makes to freeze product temperature
Rising to-20 DEG C, the time is 20 hours 20min；
It is dried: medicine is gradually heating to 0 DEG C, insulation vacuum drying 10h, is continuously heating to 25 DEG C of insulation vacuum drying 3h.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610598760.6A CN105997902A (en) | 2015-05-15 | 2015-05-15 | Ambroxol hydrochloride composition serving as medicine for treating respiratory system diseases |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610598760.6A CN105997902A (en) | 2015-05-15 | 2015-05-15 | Ambroxol hydrochloride composition serving as medicine for treating respiratory system diseases |
| CN201510247944.3A CN104860832B (en) | 2015-05-15 | 2015-05-15 | A kind of drug ambroxol hydrochloride composition for treating respiratory diseases |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510247944.3A Division CN104860832B (en) | 2015-05-15 | 2015-05-15 | A kind of drug ambroxol hydrochloride composition for treating respiratory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105997902A true CN105997902A (en) | 2016-10-12 |
Family
ID=53907071
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610598760.6A Withdrawn CN105997902A (en) | 2015-05-15 | 2015-05-15 | Ambroxol hydrochloride composition serving as medicine for treating respiratory system diseases |
| CN201610599302.4A Withdrawn CN105997905A (en) | 2015-05-15 | 2015-05-15 | Method for preparing ambroxol hydrochloride freeze-dried powder injection for treating respiratory system diseases |
| CN201510247944.3A Expired - Fee Related CN104860832B (en) | 2015-05-15 | 2015-05-15 | A kind of drug ambroxol hydrochloride composition for treating respiratory diseases |
| CN201610599487.9A Withdrawn CN106176629A (en) | 2015-05-15 | 2015-05-15 | A kind of method of the ambroxol hydrochloride freeze-dried powder injection agent preparing treatment respiratory system disease |
| CN201610598961.6A Withdrawn CN105997903A (en) | 2015-05-15 | 2015-05-15 | Ambroxol hydrochloride composition serving as medicine for treating respiratory system diseases |
| CN201610598129.6A Withdrawn CN106220517A (en) | 2015-05-15 | 2015-05-15 | A kind of method of the ambroxol compound crystal prepared for preparing ambroxol hydrochloride composition |
| CN201610598861.3A Withdrawn CN106265615A (en) | 2015-05-15 | 2015-05-15 | A kind of ambroxol compound crystal of the pharmaceutical composition for preparing treatment respiratory system disease |
| CN201610599134.9A Withdrawn CN105997904A (en) | 2015-05-15 | 2015-05-15 | Method for preparing medicinal ambroxol hydrochloride composition for treating respiratory system diseases |
Family Applications After (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610599302.4A Withdrawn CN105997905A (en) | 2015-05-15 | 2015-05-15 | Method for preparing ambroxol hydrochloride freeze-dried powder injection for treating respiratory system diseases |
| CN201510247944.3A Expired - Fee Related CN104860832B (en) | 2015-05-15 | 2015-05-15 | A kind of drug ambroxol hydrochloride composition for treating respiratory diseases |
| CN201610599487.9A Withdrawn CN106176629A (en) | 2015-05-15 | 2015-05-15 | A kind of method of the ambroxol hydrochloride freeze-dried powder injection agent preparing treatment respiratory system disease |
| CN201610598961.6A Withdrawn CN105997903A (en) | 2015-05-15 | 2015-05-15 | Ambroxol hydrochloride composition serving as medicine for treating respiratory system diseases |
| CN201610598129.6A Withdrawn CN106220517A (en) | 2015-05-15 | 2015-05-15 | A kind of method of the ambroxol compound crystal prepared for preparing ambroxol hydrochloride composition |
| CN201610598861.3A Withdrawn CN106265615A (en) | 2015-05-15 | 2015-05-15 | A kind of ambroxol compound crystal of the pharmaceutical composition for preparing treatment respiratory system disease |
| CN201610599134.9A Withdrawn CN105997904A (en) | 2015-05-15 | 2015-05-15 | Method for preparing medicinal ambroxol hydrochloride composition for treating respiratory system diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (8) | CN105997902A (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104997739A (en) * | 2015-08-31 | 2015-10-28 | 青岛蓝盛洋医药生物科技有限责任公司 | Medicine lansoprazole composition freeze-dried powder injection for treating digestive system diseases |
| CN105078883A (en) * | 2015-09-10 | 2015-11-25 | 青岛蓝盛洋医药生物科技有限责任公司 | Ambroxol hydrochloride pharmaceutical composition aqueous injection for treating diseases of respiratory system |
| CN105078896A (en) * | 2015-09-22 | 2015-11-25 | 青岛华之草医药科技有限公司 | Ambroxol hydrochloride pharmaceutical composition dry suspension for treating cough |
| CN108324693A (en) * | 2018-04-29 | 2018-07-27 | 广东伊茗药业有限公司 | A kind of double auxiliary material Ambroxol Hydrochloride for Injection freeze drying powder injections |
| CN112546007A (en) * | 2020-12-31 | 2021-03-26 | 浙江诺得药业有限公司 | Oral solid tablet containing montelukast sodium and preparation method thereof |
| CN119679767B (en) * | 2024-03-15 | 2025-09-23 | 齐鲁工业大学(山东省科学院) | Ambroxol ibuprofen eutectic dry powder inhaler, preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005113492A1 (en) * | 2004-05-20 | 2005-12-01 | Jiangsu Hansen Pharmaceutical Co., Ltd. | Cysteine analogues salts of ambroxol, preparation methods and uses thereof |
| US20080260848A1 (en) * | 2004-08-10 | 2008-10-23 | Translational Research, Ltd., | Compositions that Enable Rapid-Acting and Highly Absorptive Intranasal Administration |
| CN102600117A (en) * | 2011-01-19 | 2012-07-25 | 北京神农润田科技有限公司 | Application and preparation method of ambroxol hydrochloride in preparation of information therapeutic drug and novel drug prepared by preparation method |
| CN103073438A (en) * | 2013-02-05 | 2013-05-01 | 山东罗欣药业股份有限公司 | Ambroxol hydrochloride compound refining method |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001097856A (en) * | 1999-09-30 | 2001-04-10 | Taisho Pharmaceut Co Ltd | Antitussive |
| WO2004112746A1 (en) * | 2003-06-26 | 2004-12-29 | Korea Research Institute Of Chemical Technology | Controlled release-drug delivery system for oral administration |
| US7579505B2 (en) * | 2004-12-17 | 2009-08-25 | Cipla Limited | Crystalline levosalbutamol sulphate and polymorphic forms thereof |
| WO2008144956A1 (en) * | 2007-05-28 | 2008-12-04 | Tianjin Institute Of Pharmaceutical Research | New ambroxol compounds, their preparation processes and uses |
| CN100496464C (en) * | 2007-08-14 | 2009-06-10 | 山东罗欣药业股份有限公司 | Folic acid freeze-dried injection and preparation thereof |
| CN100506217C (en) * | 2007-08-14 | 2009-07-01 | 山东罗欣药业股份有限公司 | A kind of ambroxol hydrochloride freeze-dried powder injection and preparation method thereof |
| CN102153482B (en) * | 2011-02-28 | 2013-04-03 | 天津市铭泰医药科技有限公司 | Method for refining injection-level ambroxol hydrochloride, product and injection thereof |
| CN102516096B (en) * | 2011-11-28 | 2013-09-25 | 海南灵康制药有限公司 | Refining method of hydrochloric acid ambroxol compound |
| CN102657621B (en) * | 2012-04-28 | 2013-11-13 | 天津金耀集团有限公司 | Diltiazem hydrochloride freeze-dry powder injection for injection |
| CN103371980B (en) * | 2012-04-28 | 2017-04-26 | 天津金耀集团有限公司 | Dexamethasone sodium phosphate freeze-dried powder injection |
| CN102702001B (en) * | 2012-07-06 | 2013-08-07 | 天津梅花医药有限公司 | Stable amorphous ambroxol hydrochloride compound |
| CN102924302A (en) * | 2012-11-07 | 2013-02-13 | 陕西合成药业有限公司 | Injection-grade ambroxol hydrochloride and solution for inhalation of injection-grade ambroxol hydrochloride |
| CN102964257B (en) * | 2012-11-24 | 2014-08-06 | 沈阳新马药业有限公司 | Ambroxol hydrochloride compound and medicine composition thereof |
| CN103012167A (en) * | 2012-12-16 | 2013-04-03 | 石药集团中诺药业（石家庄）有限公司 | Preparation method of ambroxol hydrochloride |
| CN103073439B (en) * | 2013-02-05 | 2013-10-16 | 山东罗欣药业股份有限公司 | Synthesis method of ambroxol hydrochloride compound |
| CN103755577B (en) * | 2014-01-17 | 2015-11-18 | 浙江浙邦制药有限公司 | A kind of method reclaiming Transbroncho alkali from Ambroxol HCl refinement mother liquor |
| CN103864628B (en) * | 2014-02-28 | 2015-09-23 | 悦康药业集团有限公司 | Ambroxol hydrochloride compound and orally disintegrating tablet |
| CN104193627B (en) * | 2014-08-18 | 2016-05-25 | 江苏正大清江制药有限公司 | A kind of ambroxol and PCA pharmaceutical co-crystals and preparation method thereof |
-
2015
- 2015-05-15 CN CN201610598760.6A patent/CN105997902A/en not_active Withdrawn
- 2015-05-15 CN CN201610599302.4A patent/CN105997905A/en not_active Withdrawn
- 2015-05-15 CN CN201510247944.3A patent/CN104860832B/en not_active Expired - Fee Related
- 2015-05-15 CN CN201610599487.9A patent/CN106176629A/en not_active Withdrawn
- 2015-05-15 CN CN201610598961.6A patent/CN105997903A/en not_active Withdrawn
- 2015-05-15 CN CN201610598129.6A patent/CN106220517A/en not_active Withdrawn
- 2015-05-15 CN CN201610598861.3A patent/CN106265615A/en not_active Withdrawn
- 2015-05-15 CN CN201610599134.9A patent/CN105997904A/en not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005113492A1 (en) * | 2004-05-20 | 2005-12-01 | Jiangsu Hansen Pharmaceutical Co., Ltd. | Cysteine analogues salts of ambroxol, preparation methods and uses thereof |
| US20080260848A1 (en) * | 2004-08-10 | 2008-10-23 | Translational Research, Ltd., | Compositions that Enable Rapid-Acting and Highly Absorptive Intranasal Administration |
| CN102600117A (en) * | 2011-01-19 | 2012-07-25 | 北京神农润田科技有限公司 | Application and preparation method of ambroxol hydrochloride in preparation of information therapeutic drug and novel drug prepared by preparation method |
| CN103073438A (en) * | 2013-02-05 | 2013-05-01 | 山东罗欣药业股份有限公司 | Ambroxol hydrochloride compound refining method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106176629A (en) | 2016-12-07 |
| CN105997905A (en) | 2016-10-12 |
| CN106265615A (en) | 2017-01-04 |
| CN104860832B (en) | 2016-08-24 |
| CN104860832A (en) | 2015-08-26 |
| CN105997904A (en) | 2016-10-12 |
| CN105997903A (en) | 2016-10-12 |
| CN106220517A (en) | 2016-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105997902A (en) | Ambroxol hydrochloride composition serving as medicine for treating respiratory system diseases | |
| CN102702001B (en) | Stable amorphous ambroxol hydrochloride compound | |
| CN102603510B (en) | Sodium valproate crystal form as well as preparation method and application thereof | |
| CN104803860A (en) | Ambroxol hydrochloride compound and medicine composition thereof | |
| CN106349088A (en) | Method for preparing crystals of ambroxol hydrochloride compound for treating respiratory diseases | |
| CN104788421A (en) | Erdosteine compound for treating respiratory inflammation and preparation method thereof | |
| CN103739576B (en) | A kind of antivirus andrographolide derivative and its preparation method and application | |
| CN104447898B (en) | A kind of solid lactose and preparation method and application | |
| CN103751092A (en) | Valnemulin hydrochloride enteric solid dispersion, as well as preparation method and application thereof | |
| CN104829467A (en) | Ambroxol hydrochloride dihydrate compound | |
| CN110294697B (en) | Vonimulin hydrochloride hydrate crystal form and preparation method thereof and pharmaceutical composition containing the crystal form | |
| CN105055383A (en) | Ambroxol hydrochloride composition medicament for reducing phlegm | |
| CN105078883A (en) | Ambroxol hydrochloride pharmaceutical composition aqueous injection for treating diseases of respiratory system | |
| CN115124508B (en) | Preparation method and preparation of cilostazol B crystal form | |
| CN105055321A (en) | Medicinal ambroxol hydrochloride composition dry suspension for treating coughs | |
| CN105055384A (en) | Ambroxol hydrochloride medicine composition for treating cough | |
| CN104922079A (en) | Apophlegmatic medicinal ambroxol hydrochloride freeze-dried powder injection composition | |
| CN104130168B (en) | A kind of oxalic acid valnemulin crystal and preparation method thereof | |
| CN104140416B (en) | A kind of nolatrexed dihydrochloride crystal formation and preparation method and application | |
| CN105078896A (en) | Ambroxol hydrochloride pharmaceutical composition dry suspension for treating cough | |
| CN104971057A (en) | Ambroxol hydrochloride composition capsule medicine for treating respiratory system diseases | |
| CN105078917A (en) | Medical ambroxol hydrochloride composition tablets for treating respiratory organs illness | |
| CN104958317A (en) | Phlegm-eliminating medicament namely ambroxol hydrochloride composition | |
| CN106109418A (en) | Ursolic acid solid dispersion and preparation method thereof | |
| CN105982867A (en) | H009 freeze-dried powder injection and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Tang Hui Inventor after: Hu Guanghua Inventor before: Hu Guanghua |
|
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20161012 |
|
| WW01 | Invention patent application withdrawn after publication |